Dosing is underway in a Phase 1/2 clinical trial evaluating Arrowhead Pharmaceuticals’ (ARWR +3.2%) ARO-HSD in healthy volunteers and patients with nonalcoholic steatohepatitis (NASH) or suspected NASH.
The estimated completion date of the 74-subject study is November 2021.
ARO-HSD
is an RNAi therapeutic designed to dampen the production of an enzyme
called HSD17B13, a hydroxysteroid dehydrogenase that plays a key role in
the metabolism of hormones, fatty acids and bile acids. Lower activity
of the enzyme may reduce the risk of developing both alcohol-related and
non-alcohol-related liver disease.
https://seekingalpha.com/news/3548052-arrowhead-up-3-on-launch-of-new-nash-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.